Theravance Biopharma Inc.

Theravance Biopharma, Inc. develops YUPELRI, a nebulized LAMA for COPD, and Ampreloxetine for neurogenic orthostatic hypotension in MSA. It partners with Viatris on revefenacin, expanding its specialty‑pharma pipeline.

Headquarters: United States (USA)

Theravance Biopharma Inc. Logo
Company Profile
  • Employees: 97
  • HQ: South San Francisco
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
TBPH Theravance Biopharma Inc.
Cap: 1.0B | P/E: 33.4
EQUITY NMS USD KYG8807B1068 Active
📈
Home Login